A clinical stage company utilizing the world’s leading T cell-inducing platform
The patented Vaccitech adenovirus vectors are known as chimpanzee adenovirus Oxford 1 and 2 (ChAdOx1 and ChAdOx2), and are in the group E simian adenovirus family, similar to the widely-studied chimpanzee adenovirus 63. These viruses have been engineered to be replication deficient and can be manufactured in well-established HEK293 cell lines containing the adenoviral E1 gene. The viruses have very high carrying capacity for the genes encoding cancer or pathogen antigens of interest. Vaccitech further optimizes and customizes the vectors through proprietary promoters and innovative insert design in its Early Development Lab. Both ChAdOx vectors have been moved into clinical studies, with hundreds of participants receiving the intramuscular ChAdOx1 in trials for influenza, prostate cancer MERS, tuberculosis and chikungunya virus.
Adenoviral vectors represent exceptional priming agents, but are difficult to reuse in the first few months after administration due to initial anti-vector immunity. For this reason, we use a different vector (known in combination as a heterologous prime-boost) to augment the levels of the induced, polyfunctional CD4+ and CD8+ T cells. MVA is an exceptional boosting agent. Derived from the smallpox vaccine the virus was extensively cultured in avian cells to debilitate it from replicating in humans, while retaining its immunogenicity. It both boosts and prolongs polyfunctional CD4+ and CD8+ T cells induced by ChAdOx1 or ChAdOx2 and can be manufactured at scale using immortalized avian embryonic cell lines.
The Jenner Institute and Oxford University scientists has been at the forefront of the worldwide effort in using the adenoviral prime/MVA boost regimen in HIV, malaria, RSV, HCV, TB, influenza, Ebola and cancer. Vaccitech has been able to leverage this knowledge within its clinical programs that are in development and progressing rapidly.
For both of these platforms the central issues of manufacturing have been overcome, a problematic area for novel cell-based therapies. Chimpanzee and MVA vectors, including Vaccitech’s MVA universal influenza A vaccine (VTP-100), have been manufactured at scales of hundreds of litres and administered to many thousands of patients. Vaccitech has ongoing collaboration and manufacturing agreements with contract manufacturing organizations based in Europe, the United States and China.
Vaccitech has licensed the needed patents from Oxford University to advance all of the programs. Our ChAdOx1 vector patent is granted in the US and the EU, and our MVA-NP+M1 patent is granted in the EU and pending in the US.